BRAF and neuroendocrine carcinoma: As alluded to above, literature that predates the most recent WHO grading often lumps NET G3 and NEC together as “high-grade” NENs, limiting the interpretation of some of these studies as it pertains to the role of BRAF in the aggressiveness of the disease.